Skip to main content
. Author manuscript; available in PMC: 2015 Dec 16.
Published in final edited form as: Neuropharmacology. 2009 Feb 6;56(5):915–921. doi: 10.1016/j.neuropharm.2009.01.021

Fig. 3.

Fig. 3

Represent the effect of local administration of the GABAB agonists on AMPH-induced DA release (1 and 5 mg/kg) in PFC (A, B) and in STR (C, D) at indicated doses. (A) Baseline DA levels for control group getting 1 mg/kg AMPH injection 1.33 ± 0.19 pg/10 µl (n = 10), for SKF97541+1AMPH group 1.22 ± 0.12 pg/10 µl (n = 5). (B) Baseline DA levels for group getting 5 mg/kg AMPH injection 1.17 ± 0.19 pg/10 µl (n = 12), for SKF97541+5AMPH group 1.49 ± 0.41 pg/10 µl (n = 7) and for the Baclofen+5AMPH group 1.34 ± 0.24 pg/10 (n = 7). (C) Following baseline DA levels were detected: in control group getting 1 mg/kg AMPH injection 11.70 ± 2.00 pg/10 µl (n = 15) and for SKF97541 +1AMPH group 13.52 ± 1.27 pg/ 10 µl (n = 9). (D) Baseline DA levels for control group getting 5 mg/kg AMPH injection 13.13 ± 1.12 pg/10 µl (n = 14), for SKF97541 +5AMPH group 10.90 ± 1.20 pg/10 µl (n = 7) and for the Baclofen + 5AMPH group 10.50 ± 1.99 pg/10 µl (n = 9).